254 related articles for article (PubMed ID: 24288121)
1. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Owonikoko TK; Aisner J; Wang XV; Dahlberg SE; Rubin EH; Ramalingam SS; Gounder M; Rausch PG; Axelrod RS; Schiller JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):171-80. PubMed ID: 24288121
[TBL] [Abstract][Full Text] [Related]
2. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
3. Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive stage small cell lung cancer: final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124.
Lara PN; Chansky K; Shibata T; Fukuda H; Tamura T; Crowley J; Redman MW; Natale R; Saijo N; Gandara DR
Cancer; 2010 Dec; 116(24):5710-5. PubMed ID: 20737417
[TBL] [Abstract][Full Text] [Related]
4. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
7. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
[TBL] [Abstract][Full Text] [Related]
8. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
Zatloukal P; Cardenal F; Szczesna A; Gorbunova V; Moiseyenko V; Zhang X; Cisar L; Soria JC; Domine M; Thomas M
Ann Oncol; 2010 Sep; 21(9):1810-1816. PubMed ID: 20231298
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
[TBL] [Abstract][Full Text] [Related]
10. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.
Lara PN; Natale R; Crowley J; Lenz HJ; Redman MW; Carleton JE; Jett J; Langer CJ; Kuebler JP; Dakhil SR; Chansky K; Gandara DR
J Clin Oncol; 2009 May; 27(15):2530-5. PubMed ID: 19349543
[TBL] [Abstract][Full Text] [Related]
12. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH
J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Sorensen M; Lassen U; Jensen PB; Østerlind K; Jeppesen N; Jensen BB; Mellemgaard A; Rytter C; Langer SW
J Thorac Oncol; 2008 Aug; 3(8):902-6. PubMed ID: 18670309
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.
Mavroudis D; Veslemes M; Kouroussis Ch; Tzanakis N; Ferdoutsis E; Toumbis M; Ziotopoulos P; Agelidou M; Tselepatiotis E; Kalbakis K; Souglakos J; Magkanas E; Samonis G; Georgoulias V;
Lung Cancer; 2002 Oct; 38(1):59-63. PubMed ID: 12367794
[TBL] [Abstract][Full Text] [Related]
15. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE
J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
Trafalis DT; Alifieris C; Stathopoulos GP; Sitaras N
Cancer Chemother Pharmacol; 2016 Apr; 77(4):713-22. PubMed ID: 26891956
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
[TBL] [Abstract][Full Text] [Related]
20. Phase III study comparing sequential versus alternate administration of cisplatin-etoposide and topotecan as first-line treatment in small cell lung cancer.
Baka S; Agelaki S; Kotsakis A; Veslemes M; Papakotoulas P; Agelidou M; Agelidou A; Tsaroucha E; Pavlakou G; Gerogianni A; Androulakis N; Vamvakas L; Kalbakis K; Mavroudis D; Georgoulias V
Anticancer Res; 2010 Jul; 30(7):3031-8. PubMed ID: 20683051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]